Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Ontario records consecutive months of improving housing starts

March 16, 2026

Montreal-based filmmakers lead Canadian Oscar wins with animated short victory

March 16, 2026

Gas, food and travel: How the war in Iran is driving up costs in B.C.

March 16, 2026

Potential light show at Canada’s largest cemetery causes controversy

March 16, 2026

Nvidia says China’s BYD and Geely will use its robotaxi platform

March 16, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Global Amniocentesis Needle Market Analysis to 2028: NIPT Adoption Surge Sparks Demand Amid Expanding Prenatal Testing Market
Press Release

Global Amniocentesis Needle Market Analysis to 2028: NIPT Adoption Surge Sparks Demand Amid Expanding Prenatal Testing Market

By News RoomFebruary 8, 20243 Mins Read
Global Amniocentesis Needle Market Analysis to 2028: NIPT Adoption Surge Sparks Demand Amid Expanding Prenatal Testing Market
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, Feb. 08, 2024 (GLOBE NEWSWIRE) — The “Global Amniocentesis Needle Market Analysis to 2028” report has been added to ResearchAndMarkets.com’s offering.

This report on the Global Amniocentesis Needle Market forecasts a promising surge in the industry, with expected ratings of a healthy Compound Annual Growth Rate (CAGR) of 4.87% through 2028. The meticulous study underscores pivotal market drivers, including the rising average age of expectant mothers, heightened awareness of prenatal screening, a growing incidence of genetic disorders, and continuous advancements in needle technology.

The report highlights extensive industry developments, shining light on increasing maternal age as a central factor fueling market progression. Women’s tendency to delay childbearing for career or financial reasons has led to greater interest in comprehensive prenatal screening for potential chromosomal anomalies. A subsequent market driver is the escalating awareness of prenatal screening’s significance. The rise in global health education efforts and internet resources has catalyzed a demand spike for amniocentesis procedures.

Genetic disorder prevalence is on an upswing, critical to the demand for amniocentesis, a definitive prenatal diagnostic procedure. With technological advancements leading to superior needle design—improving patient safety and comfort—market growth is further stimulated. These enhancements have been instrumental in bolstering healthcare provider confidence and expanding patient access to crucial prenatal screening tools.

Yet, the emergence of alternative screening methods like NIPT (Non-Invasive Prenatal Testing) presents a challenge, offering expectant parents less invasive means of evaluating fetal health early in pregnancy. Despite these alternatives, amniocentesis remains the confirmatory standard for prenatal diagnosis. The battle between invasive and non-invasive techniques is carefully dissected, revealing potential impacts on market dynamics.

Market trends echo the rising adoption of NIPT due to its accuracy and non-invasive nature, which could influence the global demand for amniocentesis needles. Moreover, significant market expansion into emerging economies illustrates a wider embrace of prenatal testing, necessitating enhanced healthcare infrastructure for accommodating growing patient needs.

Segmental insights of the market emphasize the dominance of the amniocentesis procedure segment and project its continued growth, driven by increasing congenital disease rates. Regional insights place North America at the forefront of the market, a trend expected to persist due to vigorous healthcare developments and rising genetic disorder cases.

Key players in the Global Amniocentesis Needle Market like Becton Dickinson and Company, The Cooper Companies, Inc., Cook Medical Incorporated, and others are identified, with detailed analysis underscoring their significant market presence. These companies are critically observed for their contributions to industry growth and innovation.

This comprehensive study offers a granular investigation into the amniocentesis needle market’s present and future state, examining its various facets through pragmatic lenses. This analysis diverts attention to the ever-adaptive prenatal care landscape, highlighting factors that deliver crucial insights and drive market strategies for stakeholders worldwide.

Key Attributes

Report Attribute Details
No. of Pages 190
Forecast Period 2022-2028
Estimated Market Value (USD) in 2022 $160.02 Million
Forecasted Market Value (USD) by 2028 $213.13 Million
Compound Annual Growth Rate 4.8%
Regions Covered Global

A selection of companies mentioned in this report includes:

  • Becton Dickinson and Company
  • The Cooper Companies, Inc.
  • Cook Medical Incorporated
  • RI.MOS. srl
  • Medtronic PLC
  • Somatex Medical Technologies
  • COOK Medical
  • Smiths Medical
  • Biopsybell
  • IMD

For more information about this report visit https://www.researchandmarkets.com/r/9waeww

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  • Global Amniocentesis Needle Market

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Chef Jon-Luc Maggi of Tiki Tom’s wins Battle of the Blades in Napa, named Sysco Northern California Culinary Artisan of the Year

WeRide Showcases Robotaxi GXR Powered by NVIDIA DRIVE Hyperion Platform at NVIDIA GTC 2026, Accelerating Southeast Asia Expansion and Beyond

Prodeon Medical Receives FDA 510(k) Clearance for the Urocross® Expander System, a Novel Non-Permanent Retrievable Implant for Treating Urinary Symptoms Associated with Benign Prostatic Hyperplasia

Checkmarx Redefines Application Security for the Age of Agentic Development

ASUS TUF Gaming A14 Packs Big Power into a Portable 14-Inch Design, Now in Canada

Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT)

CyberAI Group Executes Investment Banking Agreement with Silver Leaf Partners, LLC

El Pollo Loco® Upgrades Loco Rewards® Program with Experiential Prizes, Including Coca-Cola® x El Pollo Loco Soccer Challenge

NVIDIA Vera Rubin Opens Agentic AI Frontier

Editors Picks

Montreal-based filmmakers lead Canadian Oscar wins with animated short victory

March 16, 2026

Gas, food and travel: How the war in Iran is driving up costs in B.C.

March 16, 2026

Potential light show at Canada’s largest cemetery causes controversy

March 16, 2026

Nvidia says China’s BYD and Geely will use its robotaxi platform

March 16, 2026

Latest News

Chef Jon-Luc Maggi of Tiki Tom’s wins Battle of the Blades in Napa, named Sysco Northern California Culinary Artisan of the Year

March 16, 2026

WeRide Showcases Robotaxi GXR Powered by NVIDIA DRIVE Hyperion Platform at NVIDIA GTC 2026, Accelerating Southeast Asia Expansion and Beyond

March 16, 2026

Prodeon Medical Receives FDA 510(k) Clearance for the Urocross® Expander System, a Novel Non-Permanent Retrievable Implant for Treating Urinary Symptoms Associated with Benign Prostatic Hyperplasia

March 16, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version